Elesclomol Sodium

DRUG4 trials

Sponsors

Synta Pharmaceuticals Corp., GOG Foundation

Conditions

Acute Myeloid LeukemiaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous AdenocarcinomaFallopian Tube Serous AdenocarcinomaFallopian Tube Transitional Cell CarcinomaFallopian Tube Undifferentiated CarcinomaMetastatic Solid Tumors

Phase 1

A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer

CompletedNCT00808418

Synta Pharmaceuticals Corp.Prostate Cancer

Start: 2008-11-30End: 2010-05-31Updated: 2014-02-03

A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors

SuspendedNCT00827203

Synta Pharmaceuticals Corp.Metastatic Solid Tumors

Start: 2009-01-31End: 2011-01-31Target: 30Updated: 2009-03-09

Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Synta Pharmaceuticals Corp.Acute Myeloid Leukemia

Start: 2011-01-31End: 2014-08-31Target: 36Updated: 2014-02-03

Phase 2

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

CompletedNCT00888615

GOG FoundationFallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma +15

Start: 2010-12-13End: 2016-08-31Updated: 2021-10-20

Related Papers

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.

2018-10-0869 citations